BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19277662)

  • 1. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
    Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
    Bagley RG; Roth S; Kurtzberg LS; Rouleau C; Yao M; Crawford J; Krumbholz R; Lovett D; Schmid S; Teicher BA
    Int J Oncol; 2009 May; 34(5):1329-40. PubMed ID: 19360345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
    El Hilali N; Rubio N; Blanco J
    Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
    Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
    Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells.
    Bagley RG; Kurtzberg L; Rouleau C; Yao M; Teicher BA
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1537-46. PubMed ID: 21526352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
    Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
    Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
    Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
    Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
    J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule changes in hematologic malignant cells treated with paclitaxel and comparison with vincristine cytotoxicity.
    Hirose Y; Takiguchi T
    Blood Cells Mol Dis; 1995; 21(2):119-30. PubMed ID: 8846041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
    Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
    Beyer CF; Zhang N; Hernandez R; Vitale D; Lucas J; Nguyen T; Discafani C; Ayral-Kaloustian S; Gibbons JJ
    Cancer Res; 2008 Apr; 68(7):2292-300. PubMed ID: 18381436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
    Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies of paclitaxel injection "SAWAI" and Taxol® Injection on pharmacokinetics in dogs and in vitro/vivo antitumor activities].
    Takahashi M; Hosoda M; Takahashi H; Todo S
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1699-706. PubMed ID: 20841931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
    Denardo SJ; Richman CM; Kukis DL; Shen S; Lamborn KR; Miers LA; Kroger LA; Perez EA; Denardo GL
    Anticancer Res; 1998; 18(6A):4011-8. PubMed ID: 9891439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.